Variant constraint by mRNA vaccines
- PMID: 33837367
- PMCID: PMC8034506
- DOI: 10.1038/s41577-021-00548-5
Variant constraint by mRNA vaccines
Abstract
The currently licensed mRNA vaccines for SARS-CoV-2 can elicit cross-neutralizing antibodies against B.1.351 variants of the virus, but are less potent against these variants.
Comment on
-
mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection.Science. 2021 Mar 25;372(6549):1413-8. doi: 10.1126/science.abg9175. Online ahead of print. Science. 2021. PMID: 33766944 Free PMC article.
References
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous
